Skip to content
2000
  1. Home
  2. A-Z Publications
  3. Current Medicinal Chemistry
  4. Volume 31, Issue 39
  5. Article
Volume 31, Issue 39
  • ISSN: 0929-8673
  • E-ISSN: 1875-533X

Abstract

Aim

The clinical symptoms and laboratory markers of Rheumatoid Arthritis (RA) and Psoriatic Arthritis (PsA) can be very similar, so making a differential diagnosis between these two diseases is often difficult. Serological parameters to be used in differential diagnosis can guide the clinician. This study aimed to investigate the usability of 14-3-3η (eta) protein as a biomarker in the differential diagnosis of PsA and RA, and the relationships between eta protein and disease activity scores and joint erosions in PsA and RA.

Methods

54 PsA patients, 53 RA patients, and 56 healthy individuals were included in this study. The ELISA (Enzyme-Linked ImunoSorbent Assay) kit was used as a quantitative sandwich enzyme immunoassay technique to detect human eta protein levels. Receiver-operating Characteristic (ROC) curves analysis was used to determine the sensitivity and specificity of the eta protein.

Results

Eta protein levels were found to be significantly higher in the RA group than in the PsA [B: -0.341, OR (95% CI): 0.711 (0.556-0.909), p: 0.007] and control [B: -0.225, OR (95% CI): 0.798 (0.641-0.995), p: 0.045] groups. Eta protein median values were significantly higher in patients with joint erosion than in those without [β= 0.151, OR (95% CI): 1.163 (1.003-1.349), p: 0.046].

Conclusion

Eta protein levels are higher in the serum of RA patients than PsA and are associated with joint erosion. Eta protein may be a potential biomarker in the differential diagnosis of RA and PsA. It may represent a possible therapeutic step in the pathophysiological pathways in the development of joint erosion.

© 2024 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/cmc/10.2174/0109298673295359240422115759
2024-04-27
2025-01-15

  • From This Site

    /content/journals/cmc/10.2174/0109298673295359240422115759
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. RitchlinC.T. ColbertR.A. GladmanD.D. Psoriatic Arthritis.N. Engl. J. Med.20173761095797010.1056/NEJMra150555728273019
     [Google Scholar]
  2. SmolenJ.S. LandewéR. BijlsmaJ. BurmesterG. ChatzidionysiouK. DougadosM. NamJ. RamiroS. VoshaarM. van VollenhovenR. AletahaD. AringerM. BoersM. BuckleyC.D. ButtgereitF. BykerkV. CardielM. CombeB. CutoloM. van Eijk-HustingsY. EmeryP. FinckhA. GabayC. Gomez-ReinoJ. GossecL. GottenbergJ.E. HazesJ.M.W. HuizingaT. JaniM. KarateevD. KouloumasM. KvienT. LiZ. MarietteX. McInnesI. MyslerE. NashP. PavelkaK. PoórG. RichezC. van RielP. Rubbert-RothA. SaagK. da SilvaJ. StammT. TakeuchiT. WesthovensR. de WitM. van der HeijdeD. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update.Ann. Rheum. Dis.201776696097710.1136/annrheumdis‑2016‑21071528264816
     [Google Scholar]
  3. KnaniI. BouzidiH. ZrourS. BergaouiN. HammamiM. KerkeniM. Increased serum concentrations of N ɛ -carboxymethyllysine are related to the presence and the severity of rheumatoid arthritis.Ann. Clin. Biochem.201855443043610.1177/000456321773350028882063
     [Google Scholar]
  4. Van HoovelsL. Vander CruyssenB. SieghartD. BonroyC. NagyE. PulleritsR. ČučnikS. DahleC. HeijnenI. BernasconiL. BenkhadraF. BogaertL. Van Den BremtS. Van LiedekerkeA. VanheuleG. RobbrechtJ. StudholmeL. WirthC. MüllerR. KyburzD. SjöwallC. KastbomA. JešeR. JovancevicB. KissE. JacquesP. AletahaD. SteinerG. VerschuerenP. BossuytX. IgA rheumatoid factor in rheumatoid arthritis.Clin. Chem. Lab. Med.202260101617162610.1515/cclm‑2022‑024435790193
     [Google Scholar]
  5. SmolenJ.S. Rheumatoid arthritis Primer behind the scenes.Nat. Rev. Dis. Primers2020613210.1038/s41572‑020‑0168‑y32327647
     [Google Scholar]
  6. SmolenJ.S. LandewéR.B.M. BijlsmaJ.W.J. BurmesterG.R. DougadosM. KerschbaumerA. McInnesI.B. SeprianoA. van VollenhovenR.F. de WitM. AletahaD. AringerM. AsklingJ. BalsaA. BoersM. den BroederA.A. BuchM.H. ButtgereitF. CaporaliR. CardielM.H. De CockD. CodreanuC. CutoloM. EdwardsC.J. van Eijk-HustingsY. EmeryP. FinckhA. GossecL. GottenbergJ.E. HetlandM.L. HuizingaT.W.J. KoloumasM. LiZ. MarietteX. Müller-LadnerU. MyslerE.F. da SilvaJ.A.P. PoórG. PopeJ.E. Rubbert-RothA. Ruyssen-WitrandA. SaagK.G. StrangfeldA. TakeuchiT. VoshaarM. WesthovensR. van der HeijdeD. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update.Ann. Rheum. Dis.202079668569910.1136/annrheumdis‑2019‑21665531969328
     [Google Scholar]
  7. PopescuC. ZofotăS. BojincăV. IonescuR. Anti- cyclic citrullinated peptide antibodies in psoriatic arthritis--cross-sectional study and literature review.J. Med. Life20136437638224701255
     [Google Scholar]
  8. BizzaroN. Antibodies to citrullinated peptides: a significant step forward in the early diagnosis of rheumatoid arthritis.Clin. Chem. Lab. Med.200745215015710.1515/CCLM.2007.02717311500
     [Google Scholar]
  9. BurmesterG.R. PopeJ.E. Novel treatment strategies in rheumatoid arthritis.Lancet2017389100862338234810.1016/S0140‑6736(17)31491‑528612748
     [Google Scholar]
  10. GossecL. SmolenJ.S. RamiroS. de WitM. CutoloM. DougadosM. EmeryP. LandewéR. OliverS. AletahaD. BetteridgeN. BraunJ. BurmesterG. CañeteJ.D. DamjanovN. FitzGeraldO. HaglundE. HelliwellP. KvienT.K. LoriesR. LugerT. MaccaroneM. Marzo-OrtegaH. McGonagleD. McInnesI.B. OlivieriI. PavelkaK. SchettG. SieperJ. van den BoschF. VealeD.J. WollenhauptJ. ZinkA. van der HeijdeD. European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update.Ann. Rheum. Dis.201675349951010.1136/annrheumdis‑2015‑20833726644232
     [Google Scholar]
  11. RitchlinC.T. KruegerJ.G. New therapies for psoriasis and psoriatic arthritis.Curr. Opin. Rheumatol.201628320421010.1097/BOR.000000000000027427022911
     [Google Scholar]
  12. CauY. ValensinD. MoriM. DraghiS. BottaM. Structure, function, involvement in diseases and targeting of 14-3-3 proteins: an update.Curr. Med. Chem.201825152110.2174/092986732466617042609501528462702
     [Google Scholar]
  13. MaksymowychW.P. van der HeijdeD. AllaartC.F. LandewéR. BoireG. TakP.P. GuiY. GhaharyA. KilaniR. MarottaA. 14-3-3η is a novel mediator associated with the pathogenesis of rheumatoid arthritis and joint damage.Arthritis Res. Ther.2014162R9910.1186/ar454724751211
     [Google Scholar]
  14. Doğanİ. KorA. GüvenS.C. Fırat OğuzE. BaşerS. AtalarE. MaraşY. ErelÖ. ErtenŞ. 14–3-3 η ETA protein as a potential marker of joint damage in gout.Clin. Biochem.202311811061110.1016/j.clinbiochem.2023.11061137429510
     [Google Scholar]
  15. WangD. CuiY. LeiH. CaoD. TangG. HuangH. YuanT. RaoL. MoB. Diagnostic accuracy of 14-3-3 η protein in rheumatoid arthritis: A meta-analysis.Int. J. Rheum. Dis.202023111443145110.1111/1756‑185X.1392132909672
     [Google Scholar]
  16. HammamN. SalahS. KholefE.F. MoussaE.M. MarottaA. 14-3-3η Protein in serum and synovial fluid correlates with radiographic damage and progression in a longitudinal evaluation of patients with established rheumatoid arthritis.Mod. Rheumatol.202030466467010.1080/14397595.2019.163757531242798
     [Google Scholar]
  17. HuT. LiuY. TanL. HuangJ. YuJ. WuY. PeiZ. ZhangX. LiJ. SongL. DaiW. XiangY. Value of serum collagen triple helix repeat containing-1(CTHRC1) and 14-3-3η protein compared to anti-CCP antibodies and anti-MCV antibodies in the diagnosis of rheumatoid arthritis.Br. J. Biomed. Sci.2021782677110.1080/09674845.2020.181040032813981
     [Google Scholar]
  18. KilaniR.T. MaksymowychW.P. AitkenA. BoireG. St-PierreY. LiY. GhaharyA. Detection of high levels of 2 specific isoforms of 14-3-3 proteins in synovial fluid from patients with joint inflammation.J. Rheumatol.20073481650165717611984
     [Google Scholar]
  19. WeiJ.C.C. LeongP.Y. LiuG.Y. Chaperone/scaffolding/adaptor protein 14-3-3η (eta): A diagnostic marker of rheumatoid arthritis.Int. J. Rheum. Dis.202023111439144210.1111/1756‑185X.1400433225576
     [Google Scholar]
  20. AletahaD. NeogiT. SilmanA.J. FunovitsJ. FelsonD.T. BinghamC.O.III BirnbaumN.S. BurmesterG.R. BykerkV.P. CohenM.D. CombeB. CostenbaderK.H. DougadosM. EmeryP. FerraccioliG. HazesJ.M.W. HobbsK. HuizingaT.W.J. KavanaughA. KayJ. KvienT.K. LaingT. MeaseP. MénardH.A. MorelandL.W. NadenR.L. PincusT. SmolenJ.S. Stanislawska-BiernatE. SymmonsD. TakP.P. UpchurchK.S. VencovskýJ. WolfeF. HawkerG. 2010 rheumatoid arthritis classification criteria: An American college of rheumatology/European league against rheumatism collaborative initiative.Arthritis Rheum.20106292569258110.1002/art.2758420872595
     [Google Scholar]
  21. TaylorW. GladmanD. HelliwellP. MarchesoniA. MeaseP. MielantsH. GroupC.S. CASPAR Study Group Classification criteria for psoriatic arthritis: Development of new criteria from a large international study.Arthritis Rheum.20065482665267310.1002/art.2197216871531
     [Google Scholar]
  22. MachadoP.M. RaychaudhuriS.P. Disease activity measurements and monitoring in psoriatic arthritis and axial spondyloarthritis.Best Pract. Res. Clin. Rheumatol.201428571172810.1016/j.berh.2014.10.00425488780
     [Google Scholar]
  23. NasK. KiliçE. Tekeoğluİ. KeskinY. ÇevikR. SarginB. Acer KasmanS. AlkanH. SahinN. CengizG. CüzdanN. Albayrak Gezerİ. KeskinD. MülkogluC. ReşorluH. AtamanŞ. BalA. BaykulM. DuruözM.T. KüçükakkaşO. YurdakulO.V. Alkan MelikoğluM. AyhanF.F. BodurH. ÇalişM. ÇapkinE. DevrimselG. GökK. HizmetliS. KamanlıA. KocabaşH. KutlukÖ. ŞenN. ŞendurÖ.F. ToprakM. ToluS. TuncerT. The effect of gender on disease activity and clinical characteristics in patients with axial psoriatic arthritis.Mod. Rheumatol.202131486987410.1080/14397595.2020.181287032820672
     [Google Scholar]
  24. GaripY. EserF. BodurH. Health-related quality of life in rheumatoid arthritis: comparison of RAQoL with other scales in terms of disease activity, severity of pain, and functional status.Rheumatol. Int.201131676977210.1007/s00296‑009‑1353‑120180124
     [Google Scholar]
  25. AndersonJ. CaplanL. YazdanyJ. RobbinsM.L. NeogiT. MichaudK. SaagK.G. O’dellJ.R. KaziS. Rheumatoid arthritis disease activity measures: American College of Rheumatology recommendations for use in clinical practice.Arthritis Care Res. (Hoboken)201264564064710.1002/acr.2164922473918
     [Google Scholar]
  26. Human 14-3-3 protein eta (YWHAH) ELISA kit. Available from: https://www.cusabio.com/ELISA-Kit/Human-14-3-3-protein-etaYWHAH-ELISA-kit-112977.html#a05
  27. SalmanE. Çeti̇nerS. BoralB. Ki̇barF. ErkenE. ErsözlüE.D. BadakS.Ö. Bi̇li̇ci̇ SalmanR. Sertdemi̇rY. Çeti̇n DuranA. YamanA. Importance of 14-3-3 eta, anti- CarP, and anti-Sa in the diagnosis of seronegative rheumatoid arthritis.Turk. J. Med. Sci.20194951498150210.3906/sag‑1812‑13731651120
     [Google Scholar]
  28. GuanS.Z. YangY.Q. BaiX. WangY. FengK.Q. ZhangH.J. DongM. YangH.W. LiH.Q. Serum 14-3-3η could improve the diagnostic rate of rheumatoid arthritis and correlates to disease activity.Ann. Clin. Lab. Sci.2019491576230814078
     [Google Scholar]
  29. Souto-CarneiroM. TóthL. BehnischR. UrbachK. KlikaK.D. CarvalhoR.A. LorenzH.M. Differences in the serum metabolome and lipidome identify potential biomarkers for seronegative rheumatoid arthritis versus psoriatic arthritis.Ann. Rheum. Dis.202079449950610.1136/annrheumdis‑2019‑21637432079570
     [Google Scholar]
  30. GongX. XuS. WuY. MaC. QiS. LiuW. XuJ. Elevated serum 14-3-3η protein may be helpful for diagnosis of early rheumatoid arthritis associated with secondary osteoporosis in Chinese population.Clin. Rheumatol.201736112581258710.1007/s10067‑017‑3807‑228875246
     [Google Scholar]
  31. MaksymowychW.P. NaidesS.J. BykerkV. SiminovitchK.A. van SchaardenburgD. BoersM. LandewéR. van der HeijdeD. TakP.P. GenoveseM.C. WeinblattM.E. KeystoneE.C. ZhukovO.S. AbolhosnR.W. PopovJ.M. BritsemmerK. van KuijkA.W. MarottaA. Serum 14-3-3η is a novel marker that complements current serological measurements to enhance detection of patients with rheumatoid arthritis.J. Rheumatol.201441112104211310.3899/jrheum.13144625128504
     [Google Scholar]
  32. CarrierN. MarottaA. de Brum-FernandesA.J. LiangP. MasettoA. MénardH.A. MaksymowychW.P. BoireG. Serum levels of 14-3-3η protein supplement C-reactive protein and rheumatoid arthritis-associated antibodies to predict clinical and radiographic outcomes in a prospective cohort of patients with recent-onset inflammatory polyarthritis.Arthritis Res. Ther.20161813710.1186/s13075‑016‑0935‑z26832367
     [Google Scholar]
  33. QuC.H. HouY. BiY.F. HanQ.R. JiaoC.H. ZouQ.F. Diagnostic values of serum IL-10 and IL-17 in rheumatoid arthritis and their correlation with serum 14-3-3η protein.Eur. Rev. Med. Pharmacol. Sci.20192351899190630915732
     [Google Scholar]
  34. MaksymowychW.P. BoireG. van SchaardenburgD. WichukS. TurkS. BoersM. SiminovitchK.A. BykerkV. KeystoneE. TakP.P. van KuijkA.W. LandewéR. van der HeijdeD. MurphyM. MarottaA. 14-3-3η autoantibodies: diagnostic use in early rheumatoid arthritis.J. Rheumatol.20154291587159410.3899/jrheum.14138526178283
     [Google Scholar]
  35. HirataS. MarottaA. GuiY. HanamiK. TanakaY. Serum 14-3-3η level is associated with severity and clinical outcomes of rheumatoid arthritis, and its pretreatment level is predictive of DAS28 remission with tocilizumab.Arthritis Res. Ther.201517128010.1186/s13075‑015‑0799‑726449724
     [Google Scholar]
  36. KorA. YalçınM. ErtenŞ. MaraşY. OğuzE.F. Doğanİ. AtalarE. BaşerS. ErelÖ. 14-3-3η proteins as a diagnostic marker, disease activation indicator, and lymphoma predictor in patients with primary sjögren syndrome.Arch. Iran Med.2023261058259110.34172/aim.2023.8538310415
     [Google Scholar]
/content/journals/cmc/10.2174/0109298673295359240422115759
Loading
Does Eta Protein Differentiate Rheumatoid Arthritis from Psoriatic Arthritis?
Curr. Med. Chem. 31, 6510 (2024); https://doi.org/10.2174/0109298673295359240422115759
/content/journals/cmc/10.2174/0109298673295359240422115759
/content/journals/cmc/10.2174/0109298673295359240422115759
Loading

Data & Media loading...


  • Article Type:     Research Article
Keyword(s): 14-3-3η protein; disease activity; joint erosion; psoriatic arthritis; rheumatoid arthritis; visual analog scale

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test